We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical
RARE

81 hedge funds and large institutions have $816M invested in Ultragenyx Pharmaceutical in 2014 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 31 increasing their positions, 26 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 9

19% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 26

17% more call options, than puts

Call options by funds: $293K | Put options by funds: $251K

5% more funds holding

Funds holding: 77 → 81 (+4)

0% more capital invested

Capital invested by funds: $815M → $816M (+$1.1M)

Holders
81
Holders Change
+4
Holders Change %
+5.19%
% of All Funds
2.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
31
Reduced
26
Closed
9
Calls
$293K
Puts
$251K
Net Calls
+$42K
Net Calls Change
+$42K

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$37.4M
2
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$7.32M
3
Citadel Advisors
Citadel Advisors
Florida
+$6.34M
4
CI
Cowen Inc
New York
+$5.78M
5
Goldman Sachs
Goldman Sachs
New York
+$2.67M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$5.67M
2
TCP
Tourbillon Capital Partners
New York
-$3.91M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$3.45M
4
Jennison Associates
Jennison Associates
New York
-$2.68M
5
Millennium Management
Millennium Management
New York
-$2.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
DCM
26
Driehaus Capital Management
Illinois
$4.12M +$1.23M +29,921 +48%
State Street
27
State Street
Massachusetts
$4.12M +$1.15M +27,889 +44%
Northern Trust
28
Northern Trust
Illinois
$3.9M +$2.38M +57,872 +200%
BIT
29
BlackRock Institutional Trust
California
$3.6M -$1.03M -25,136 -24%
WMSA
30
Weiss Multi-Strategy Advisers
New York
$3.56M +$159K +3,850 +5%
RSCM
31
Rock Springs Capital Management
Maryland
$2.94M +$576K +14,000 +27%
PI
32
Putnam Investments
Massachusetts
$2.91M – – –
EAM
33
Eventide Asset Management
Massachusetts
$2.36M +$2.17M +52,600 New
TG
34
TCW Group
California
$2.33M +$1.14M +27,720 +115%
BIM
35
BlackRock Investment Management
Delaware
$2.04M +$1.09M +26,546 +140%
OM
36
Opaleye Management
Massachusetts
$2.02M +$1.85M +45,000 New
Morgan Stanley
37
Morgan Stanley
New York
$1.98M -$1.56M -37,951 -46%
IHM
38
Iguana Healthcare Management
New York
$1.88M -$543K -13,200 -24%
EA
39
Emerald Advisers
Pennsylvania
$1.74M +$496K +12,040 +45%
Geode Capital Management
40
Geode Capital Management
Massachusetts
$1.65M +$32K +778 +2%
EMFAT
41
Emerald Mutual Fund Advisers Trust
Pennsylvania
$1.56M +$502K +12,204 +54%
JHIU
42
Janus Henderson Investors US
Colorado
$1.45M -$1.16M -28,135 -47%
Bank of New York Mellon
43
Bank of New York Mellon
New York
$1.34M +$435K +10,571 +55%
BA
44
BlackRock Advisors
Delaware
$1.2M -$2.62M -63,584 -70%
RFS
45
Rockefeller Financial Services
New York
$1.17M +$592K +14,380 +123%
TCIM
46
TIAA CREF Investment Management
New York
$1.15M +$62K +1,505 +6%
PAM
47
Panagora Asset Management
Massachusetts
$1.15M -$57.2K -1,389 -5%
Axa
48
Axa
France
$936K – – –
Brown Advisory
49
Brown Advisory
Maryland
$896K -$659 -16 -0.1%
NFA
50
Nationwide Fund Advisors
Ohio
$788K +$306K +7,422 +73%
1
2
3 4

RARE Hedge Fund Activity: Q2 2014 in Review

81 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2014, worth a combined $816M — up 0.14% from $815M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new RARE positions and 9 closed out — a net gain of 5 holders — while 31 added to existing stakes and 26 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $37.4M. The largest seller was T. Rowe Price Associates, cutting an estimated $5.67M.

  • 81 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2014, up from 77 in Q1 2014.
  • Funds reported $816M of Ultragenyx Pharmaceutical stock for Q2 2014, up 0.14% quarter-over-quarter.
  • 14 funds opened new Ultragenyx Pharmaceutical positions in Q2 2014 and 9 closed out, a net change of +5 holders.
  • The largest Ultragenyx Pharmaceutical buyer in Q2 2014 was Fidelity Investments, an estimated $37.4M added.
  • The largest Ultragenyx Pharmaceutical seller in Q2 2014 was T. Rowe Price Associates, an estimated $5.67M sold.

Based on aggregated 13F filings for Q2 2014.